Making the undruggable druggable
Unlocking challenging drug targets for the development of next-generation therapeutics
Selected Collaborations
It all starts with the drug target.
The majority of drug targets are so-called membrane proteins, and these are inherently unstable and challenging to investigate. Or so they were, until now.
Our proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies or small molecule drugs. Through our in-house and partnered pipelines, we drive the discovery of novel drugs.
Pushing drug development forward together
We work with top-tier pharma and biotech partners to unlock drug targets for drug development programs.
Pipeline
We are driving forward drug development in our partnered as well as internal pipelines.
News
Collaboration and Licensing Agreement with Top Tier South Korean Pharma Company
2025-03-05
Salipro has entered into a collaboration and licensing agreement with one of the top tier pharmaceutical companies in South Korea.
This partnership leverages Salipro Biotech’s expertise and proprietary technology (Salipro®) to stabilise challenging drug targets including GPCRs, ion channels and transporters, making them accessible for the development of next-generation therapeutics.
Stay tuned for more updates as we continue to expand our global footprint in our mission to make the undruggable druggable!
Salipro to present at NextGen Biomed 2025
2025-03-03
Join us next week at NextGen Biomed 2025 in London, UK (March 12-14)!
Our Senior Scientist, Anne-Sophie Åstrand-Tournillon, will be there to present a poster on the latest advancements with the Salipro® platform for biologics targeting membrane protein drug targets.
This is a fantastic opportunity to connect with us. Be sure to stop by Anne-Sophie’s poster and say hello to her.
We look forward to connecting with you there!
Find more information on NextGen Biomed on their website: https://oxfordglobal.com/nextgen-biomed/events/nextgen-biomed
Salipro to attend BIO-Europe Spring 2025
2025-02-20
Let’s connect at BIO-Europe Spring!
Salipro Biotech will be attending BIO-Europe Spring 2025, taking place in Milan (Italy), March 17-19!
Our Business Development team, Lorena Galán and Peter Jahnmatz, will be on-site to discuss our latest advancements on Salipro® platform and explore new collaboration opportunities to accelerate the development of next-generation therapeutics.
Join us in Milan to explore ways we could work together to advance drug discovery programs targeting membrane proteins.
Schedule a meeting with Lorena and Peter via the platform: https://partneringone.informaconnect.com/event/791/profile/user/440/company/292
We look forward to in-person business meetings with current and future pharma and biotech partners!